This Phase II trial, sponsored by SCRI Development Innovations, LLC, evaluates a combination therapy of Irinotecan, Carboplatin, and Radiation Therapy followed by Bevacizumab in patients with limited stage small cell lung cancer (LS-SCLC). Given the high unmet need in LS-SCLC, successful outcomes could position this regimen favorably in a competitive landscape dominated by existing therapies. The trial's completion and subsequent results could provide critical data for potential partnerships or licensing opportunities, particularly with collaborators Genentech, Inc. and Pharmacia and Upjohn, who have vested interests in oncology therapeutics. The market for lung cancer treatments is substantial, with ongoing demand for improved efficacy and safety profiles, particularly in combination therapies.